Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
- MinuteCE®
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
1.00 program creditBørge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
